From Gut to Nucleus: Microbiome-Derived Metabolites as Modulators of HIF Signaling in Hypoxic Tissues

Inspired by Guo et al. (2024), who found gut-derived tyrosol can inhibit HIF-1α in colorectal cancer, this idea proposes to broaden the scope by profiling a library of microbiome-derived metabolites for their ability to modulate HIF signaling in various hypoxia-sensitive tissues (e.g., brain, heart, kidney). Using organoid cultures and hypoxia chambers, high-throughput screens could identify metabolites that either potentiate or suppress HIF activity. Mechanistic studies (e.g., proteomics, ChIP-seq) would then clarify how these small molecules interface with HIF regulation—directly (modifying HIF stability) or indirectly (epigenetic/ROS-mediated). This research could uncover a new axis of host-microbiome communication with direct implications for treating hypoxia-related disorders or enhancing tissue resilience.

References:

1. Inhibition of the NF-κB/HIF-1α signaling pathway in colorectal cancer by tyrosol: a gut microbiota-derived metabolite. Jian Guo, Fanqi Meng, Ruixue Hu, Lei Chen, Jiang Chang, Ke Zhao, Honglin Ren, Zengshan Liu, Pan Hu, Guangyi Wang, Jiandong Tai (2024). Journal for ImmunoTherapy of Cancer.